Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Plasma Cell Myeloma

In brief

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.

Key facts

Study ID

NCT04211259

Run by

Rutgers, The State University of New Jersey

People needed

70

Starts

2022-04-18

Expected to finish

2027-06-30

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must be able to provide informed consent
• Patients with confirmed diagnosis of multiple myeloma
• Able to swallow and retain oral medication
• All ethnic groups are eligible

You may not qualify if…

• Non-English speaking person
• Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
• Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
• Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
• On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study

Where it is running

• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
• RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick — New Brunswick, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.